- | Fore Biotherapeutics
Q: How have evolving technologies like artificial intelligence (AI) and machine learning (ML) changed how you conduct research, manufacturing, or business?
At Fore Biotherapeutics, we are leveraging our functional genomics platform, Foresight, to match populations of patients with rare cancer mutations to targeted therapies that have a high probability of making a difference. Our mission is to provide patients with unaddressed cancer mutations with rapid access to the right medicines.
- | BeyondSpring Pharmaceuticals
BeyondSpring Pharmaceuticals (BYSI) CEO Joins The Watch List
The BeyondSpring Pharmaceuticals CEO Dr. Lan Huang talks through receiving U.S. FDA and China NMPA acceptance of its new drug application with priority review for use of its lead product Plinabulin. Huang says early clinical data supports Plinabulin as a direct anti-cancer agent in combination with PD1/PDL1 inhibitors in small cell lung cancer.
- | 9 Meters Biopharma
9 Meters ahead of the rest in fight against celiac disease
Getting celiac disease (CD) diagnosed can be a long and difficult path for patients, and with no effective…
- | Vaxart
The next generation Covid-19 vaccines seeking a slice of the market
Latecomers hope size, price or novel technology mean they can still play an important role in the pandemic
- | Palisade Bio
Accelerating Return of Gastrointestinal Function After Major Surgery with Tom Hallam Palisade Bio
Tom Hallam PhD is CEO of Palisade Bio a late stage biopharmaceutical company with a focus on gastrointestinal complications from major surgery and getting patients out of the hospital more quickly. With discoveries about how digestive enzymes can hurt a patient’s gastrointestinal tract, their lead asset LB1148 is a liquid that the patient drinks prior to surgery. This drug coats the entire gastrointestinal tract and inhibits digestive enzymes preventing them from attacking underlying tissue.
- | Clene Nanomedicine
Clene pioneering therapeutic nanocatalysts to improve cellular bioenergetics
Clene (NASDAQ:CLNN) is developing a novel approach for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease, using nanocatalysts in order to enhance cellular energy production.
- | Selecta Biosciences
Challenges and opportunities in gene therapy development
Despite the promise of gene therapies, significant challenges have emerged in the field. Dr Carsten Brunn discusses the current obstacles and opportunities when developing gene therapies.
- | Orasis Pharmaceuticals
Pipeline: Presbyopia treatment to finish Phase 3 late 2021
Orasis Pharmaceuticals CEO and founder Elad Kedar says the company is looking to achieve a balance of safety, efficacy, and comfort with its drop in development for treating presbyopia. He says Phase 3 studies should finish at the end of 2021.
